Paul R. Rosie

Mr. Rosie’s client representations include:

Mergers and Acquisitions

• Abide Therapeutics in its sale to Lundbeck
• HealthEdge in its sale to Blackstone
• Helio Vision in its sale to Aldeyra Therapeutics
• iRobot Corporation in its acquisition of Robopolis SAS
• LoJack Corporation in its $135 million sale to CalAmp Corp.
• Mitralign in its sale to Edwards Lifesciences Corporation

Private Financings

• Allurion Technologies in its $27 million Series C financing
• ClimaCell in its Series B and C financings
• Imagen Technologies in its preferred stock financings
• Jobcase in its $100 million growth equity financing
• PatientPing in its $31 million Series B financing

Public Offerings

• argenx SE in its $115 million initial U.S. public offering
• BeiGene, Ltd. in its $200 million, $201 million and $800 million follow-on public offerings
• Proteostasis Therapeutics, Inc. in its $40 million follow-on public offering
• Underwriters in Ibex Limited’s $90 million initial public offering

Mr. Rosie is a member of the Boston Bar Association. He holds office hours at the Harvard Innovation Lab and he has served as a mentor for the MIT $100K Entrepreneurship Competition.

Mr. Rosie rejoined Goodwin in 2018 after serving as a senior corporate counsel at Pegasystems, where he worked on SEC compliance, mergers and acquisitions, and its corporate venture program. Prior to joining the firm, Mr. Rosie served as a senior corporate counsel at athenahealth, where he advised on corporate governance and securities matters, mergers and acquisitions, and the launch of athenahealth’s More Disruption Please innovation and partnership program.